ESMO 2021 Bladder Cancer - Results from #20

Viewing 21-27 of 27 articles

ESMO 2021: Atezolizumab Monotherapy in Cisplatin-Ineligible Patients with Previously Untreated Metastatic Urothelial Carcinoma: 5-Year Response and Survival Analysis from the Phase II IMvigor210 Study (Cohort 1)

ESMO 2021: Analysis of Hard-to-Treat Subgroups from EV-301, a Phase 3 Trial of Enfortumab Vedotin (EV) vs Chemotherapy for Previously Treated Advanced Urothelial Carcinoma

ESMO 2021: Treatment Patterns Among Patients With Advanced Urothelial Carcinoma in the US

ESMO 2021: PD-L1 as a Predictor of Survival in Patients With Metastatic Urothelial Carcinoma From the Phase 3 DANUBE Trial of Durvalumab or Durvalumab Plus Tremelimumab Versus Standard of Care Chemotherapy

ESMO 2021: SunRISe-1: TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High Risk NMIBC Unresponsive to Intravesical BCG Who Are Ineligible for or Elected Not To Undergo Radical Cystectomy

ESMO 2021: New Developments in Muscle-Invasive Bladder Cancer

ESMO 2021: How To Choose First-Line Systemic Therapy in Advanced Urothelial Cancer

1
2